The Evolving Role of CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

Bijal Shah, MD, MS, and Jae Park, MD, deliver the key data and insights for CAR T-cell therapy in acute lymphoblastic leukemia.

EP. 1: Dissecting the Impact of Obe-Cel on the ALL Treatment Paradigm

June 24th 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss how the integration of obe-cel has affected the acute lymphoblastic treatment paradigm.

EP. 2: Outcomes With Obe-Cel in ALL: An Age-Based Analysis of the FELIX Trial

June 24th 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss an age-based analysis of outcomes with obe-cel in acute lymphoblastic leukemia.

EP. 3: Long-Term Data and Predictors of Sustained Remission With Obe-Cel in ALL

July 2nd 2025

Bijal Shah, MD, MS, and Jae Park, MD, predictors of sustained remission with obe-cel in acute lymphoblastic leukemia.

EP. 4: Correlation Between Inotuzumab Exposure and Obe-Cel Efficacy in ALL

July 2nd 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss how inotuzumab exposure may influence response to obe-cel in ALL.

EP. 5: Other Key Data in ALL Presented at EHA 2025

July 9th 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss other key data in acute lymphoblastic leukemia from EHA 2025.

EP. 6: QOL Data With Obe-Cel in Acute Lymphoblastic Leukemia

July 9th 2025

Bijal Shah, MD, MS, and Jae Park, MD, discuss quality-of-life data for obe-cel in acute lymphoblastic leukemia.

x